(function(doc, html, url) { var widget = doc.createElement("div"); widget.innerHTML = html; var script = doc.currentScript; // e = a.currentScript; if (!script) { var scripts = doc.scripts; for (var i = 0; i < scripts.length; ++i) { script = scripts[i]; if (script.src && script.src.indexOf(url) != -1) break; } } script.parentElement.replaceChild(widget, script); }(document, '

Effects of safinamide on chronic pain in Parkinsonian patients

What is it about?

safinamide is a drug with a double mechanism of action, dopaminergic and non-dopaminergic. Safinamide modulates the release of glutamate, and glutamate is believed to be involved in dyskinesia, chronic pain and mood disorders in Parkinson's Disease patients. With this analysis safinamide has shonw to be effective in mitigate the neuropathic pain of PD patients, and reduce the concomitant use of analgesics of about 24%.

Why is it important?

Up to 80% of Parkinsonian patients suffer for chronic pain and at there are no drugs for this comorbidity. Patients use several pain killer drugs, such as analgesics, antinflammatories and opiodis, with several adverse events.

Read more on Kudos…
The following have contributed to this page:
Carlo Cattaneo
' ,"url"));